Navigation Links
Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
Date:9/25/2011

c and rapidly progressive and can result in right ventricular heart failure and death(4). An estimated 260,000 people are affected worldwide(3) and approximately half of the people diagnosed with PAH die within five years,(10).

"If approved, QTI571 has the potential to provide a further treatment option for patients where current therapies are not providing sufficient benefit in the treatment of this life-threatening disease," said David Epstein, Division Head of Novartis Pharmaceuticals. "Novartis has a strong and growing portfolio of respiratory medicines, and we are committed to expanding the support we offer to patients suffering from a number of respiratory and pulmonary disorders."

QTI571 is an oral therapy that works by inhibiting the activity of proliferative factors including platelet-derived growth factor (PDGF) which is thought to be involved, along with its receptor, in the progression of PAH(10,11). In patients with this disease, PDGF may cause smooth muscle cells in the pulmonary arteries to multiply, restricting blood flow and increasing resistance in these arteries(12).

Safety data showed that the overall incidence of adverse events was similar for QTI571 and for placebo(1). Serious adverse events and discontinuations due to serious adverse events were more frequent with QTI571(1). Adverse events were as expected for this patient population and class of drug, and were similar to those previously reported with QTI571(13).

IMPRES was a 24-week randomized placebo-controlled, double-blind, multi-center clinical trial evaluating the efficacy and safety of oral QTI571 as an add-on therapy in the treatment of patients with PAH(1). The study involved a total of 202 patients with elevated PVR of >800 dynes.sec.cm-5 despite treatment with at least two other specific PAH medications (i.e. endothelin receptor antagonists, phosphodiesterase-5 inhibitors and/or prostacyclins)(1).

Treatment was initiated at a dose of 2
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- Seres Health, a clinical-stage therapeutics company developing novel treatments ... that it has been named by FierceBiotech ... it as one of the most promising private biotechnology ... great deal of ain,t-it-cool science in microbiomics, Seres Health ... therapeutic development," says Damian Garde , editor of ...
(Date:9/22/2014)... , Sept. 22, 2014 Thoratec Corporation ... device-based mechanical circulatory support therapies to save, support and ... Grossman has been appointed President and Chief Executive ... , who has stepped down from his executive and ... the company through the first quarter of 2016.  ...
(Date:9/22/2014)... Sept. 22, 2014  Prostate cancer is the second ... is easily treated when caught early - the problem ... why the Prostate Conditions Education Council (PCEC), ... a leader in prostate cancer screening –  is sponsoring ... (PCAW) from September 22-27.  Committed to ...
Breaking Medicine Technology:Seres Health Named a "Fierce 15" Biotech Company for 2014 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3
... Today, Roche honored 11 outstanding Ph.D. students and two professors with ... the field of organic chemistry. The winners are participating in Roche,s annual ... first hand knowledge on the important role organic chemistry plays in pharmaceutical ... "This symposium ...
... PARIS , June 3, 2010 ... organisation bringing together global,forces in personalised medicine, has today ... entrepreneur in personalised healthcare, as Executive,Director and board member. ... and, together with the board of directors, for building,its ...
Cached Medicine Technology:Roche Symposium Showcases Accomplishments of Next Generation of Chemists 2Roche Symposium Showcases Accomplishments of Next Generation of Chemists 3Roche Symposium Showcases Accomplishments of Next Generation of Chemists 4Roche Symposium Showcases Accomplishments of Next Generation of Chemists 5EPEMED, the European Personalised Medicine Association, Appoints Executive Director 2EPEMED, the European Personalised Medicine Association, Appoints Executive Director 3
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Scans of young children,s brains might help predict ... potentially allow doctors to identify those with dyslexia ... suggests. "Early identification and interventions are extremely ... most neurodevelopmental disorders," the study,s senior author, Dr. ... adolescent psychiatry at University of California, San Francisco ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The struggles ... English proficiency (LEP) patients has been well-documented—reportedly, language barriers ... repeat visits to the emergency room and an increased ... , At Sanford Health, the largest medical facility ... a rising LEP population necessitated the need for ...
(Date:9/22/2014)... Tenn. (PRWEB) September 22, 2014 ... contact center and customer service solutions. , WHAT: ... is focused on customer care for the connected ... landscapes continue to offer new challenges and opportunities ... to helping attendees identify best practices, network and ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... is associated with an increased risk of heart failure and ... concludes a study published on bmj.com today. ... continued use of rosiglitazone for most patients. Rosiglitazone and ... are widely used for the treatment of type 2 diabetes. ...
... year, 500,000 project to co-ordinate European and international ... treat malaria. The CRIMALDDI project (Coordination, Rationalisation ... Initiatives) is being led by the Liverpool School ... players in the antimalarial drug discovery fields including ...
... Having 45 million doses by Oct. 15 will still be ... Health experts do not believe that the delay in receiving ... protect Americans against the newly circulating virus. , But having ... than the originally anticipated 120 million doses, does throw a ...
... , MONROVIA, Calif., Aug. 20 STAAR Surgical Company ... minimally invasive ophthalmic products, today reported on the status of its application ... , , As anticipated, the Ministry of Health, Labour ... in Japan, at which time the STAAR Visian ICL products were considered ...
... ... and innovative charitable program that provides free hair restoration services to children suffering from ... ... , the world,s first online social network community dedicated to all-things hair loss has ...
... ... Sparsense, the developer of a novel image and signal processing ... firm. The exclusive partnership will allow the development of various custom ... applications. The new technology can be applied to MRI, MR video ...
Cached Medicine News:Health News:Diabetes drug linked to increased risk of heart failure 2Health News:LSTM to lead EU project to coordinate antimalarial drug research 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 2Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 4Health News:Hair Loss Website Launches Program for Children 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: